Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

pRESET for Occlusive Stroke Treatment

NCT03994822 · View on ClinicalTrials.gov ↗

Study Summary

Compare the safety and effectiveness of pRESET to Solitaire in the treatment of stroke related to large vessel occlusion

Interventions

  • DEVICE Mechanical Thrombectomy using the pRESET Thrombectomy device
  • DEVICE Mechanical Thrombectomy using the Solitaire Revascularization Device

Study Locations (20)

New York

  • Buffalo General Medical Center — Buffalo
  • NYU Langone Health — New York
  • The Mount Sinai Hosptial — New York
  • Montefiore Medical Center — The Bronx

Florida

  • University of Miami — Coral Gables
  • Baptist Health Research Institute Jacksonville — Jacksonville

Illinois

  • Rush University Medical Center — Chicago
  • Advocate Lutheran General Hospital — Downers Grove

Arizona

  • Honor Health Research Institute — Scottsdale

California

  • Providence Little Company of Mary Medical Center — Santa Monica

Georgia

  • Grady Memorial Hospital — Atlanta

Iowa

  • University of Iowa Hospitals and Clinics — Iowa City

Massachusetts

  • University of Massachusetts — Worcester

Trial Details

FieldValue
Enrollment Target 340 participants
Start Date 2019-10-04
Est. Completion 2022-05-12
Phase NA

Sponsor

phenox

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03994822

The ClinicalTrials.gov registry entry for NCT03994822 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is phenox, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 10 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions — of which Mechanical Thrombectomy using the pRESET Thrombectomy device is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03994822 reports 20 study locations spanning 15 distinct geographic areas — top geographies include New York, Florida, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03994822 about?

NCT03994822 is a clinical study titled "pRESET for Occlusive Stroke Treatment". Compare the safety and effectiveness of pRESET to Solitaire in the treatment of stroke related to large vessel occlusion

What is the current status of trial NCT03994822?

This trial is currently completed. It is a NA study. The enrollment target is 340 participants. The study started on 2019-10-04. Estimated completion is 2022-05-12.

What conditions does trial NCT03994822 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Vascular Diseases, Stroke, Ischemic, Stroke, Acute, Nervous System Diseases. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03994822?

The interventions under investigation include: Mechanical Thrombectomy using the pRESET Thrombectomy device (DEVICE), Mechanical Thrombectomy using the Solitaire Revascularization Device (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03994822?

This trial is sponsored by phenox, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03994822 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial